TTC-352

TTC-352 is an orally bioavailable selective human estrogen receptor (ER) α partial agonist (ShERPA) . TTC-352 inhibits the growth of three ER+ breast cancer cells. TTC-352 induces tumor regression accompanied by exit of ERα from the nucleus to extranuclear sites[1][2].

Product Specifications

CAS Number

[1607819-68-0]

UNSPSC

12352005

Target

Estrogen Receptor/ERR

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ttc-352.html

Smiles

OC1=CC=C(C(C2=CC=C(F)C=C2)=C(OC3=CC=C(O)C=C3)S4)C4=C1

Molecular Formula

C20H13FO3S

Molecular Weight

352.38

References & Citations

[1]Tonetti D A, et al. Efficacy, maximal tolerated dose, and toxicokinetics of TTC-352 in rats and dogs, a partial ER agonist for metastatic ER+ breast cancer[J]. 2017.|[2]Molloy ME, et al. Novel selective estrogen mimics for the treatment of tamoxifen-resistant breast cancer. Mol Cancer Ther. 2014 Nov;13 (11) :2515-26.